nucleic acids into therapeutic solutions





## DELIVERY PLATFORM TO TURN NUCLEIC ACIDS INTO THERAPEUTIC SOLUTIONS

#### **Table of Contents**

An introduction to our delivery platform: Lipopolymers	2
Mechanism of action for RJH Lipopolymers	3
Formulations for different applications (cells and nucleic acids)	4
Use of Lipopolymers in animal models	5
Use of Lipopolymers for modification of suspension cells	6
Bioactivity of aerosolized formulations	7
Screening services provided by RJH Biosciences	8
CRISPR applications of Lipopolymers	9
Large scale production of RJH reagents	10
Spectrum of applications	11

# Our platform lipopolymers for delivering nucleic acids into cells

Combinations of **lipids** and **polymers** for effective delivery of nucleic acids: optimized for size, composition, stability, and architecture.



#### Superior to current delivery vehicles

#### Viruses





#### **Polymers**






#### Lipid particles






Easier to manufacture than LNPs

### Mechanism of action for lipopolymer-mediated nucleic acid delivery




# Formulations for different applications

#### I. Different cell types



#### II. Different nucleic acids



Transfecting attachment-independent K562 cells with plasmid DNA and siRNA using ALL-Fect and a leading lipofection reagent.


- A) GFP expression was induced with plasmid DNA and analyzed by flow cytometry 2 days after transfection.
- B) Survivin silencing and resultant inhibition of cell growth with specific siRNA 3 days after transfection.

# Efficacious delivery in animal models


## I. Expression of reporter GFP gene in implants with pDNA




# II. Repair of bone (skull) defects with implantation of pDNA



## III. Inhibition of tumor growth with siRNA injections



# IV. Inhibition of tumor growth with local mRNA injections




Weight of explanted breast cancer tumors (day 17) for nontreated (NT), GFP and TRAIL expressing mRNAs. \* and \*\* indicate


significant differences between TRAIL mRNA and mGFP and NT groups.

# Superior delivery of mRNA and pDNA in suspension cells

#### I. pDNA (GFP) delivery



#### II. mRNA (GFP) delivery




#### Effective Modification of Human PBMC with pDNA and mRNA


( numbers indicate optimal reagent : nucleic acid w/w ratio )

# Formulations for aerosolized transfection


GFP Expression with Aerosolized pDNA Particles



#### GFP Silencing with Aerosolized siRNA Particles




#### mRNA Delivery with Aerosolized mRNA Particles




# Optimization and development of reagents through screening services

## Screening siRNA libraries with RJH reagents for biomarker discovery





# Screening for optimal delivery vehicles in different cell types




# **CAS9 delivery** for CRISPR activity


## I. Transfection for efficient pDNA-based editing of target genes





## II. Improved delivery of Cas9/sgRNA RNP superior to leading lipofection reagent





### RJH lipopolymers are suitable for large scale production



Large-scale animal studies

gram product



#### 2022/3

GLP/GMP production for clinical use

kilogram product



2020

**Exploratory** research milligram product






Our products are now produced at a scale suitable for animal studies



Custom transfection reagents produced on demand

### **Spectrum** of applications

#### **Publication topics with RJH reagents**



#### Cell lines

- ▶ MDCK epithelial cells
- ▶ 293T kidney fibroblasts
- ► MDA-231/436, SUM-149PT, MCF-7 breast cancer cells
- ► AML THP-1, KG1/A, HL60 cells
- ▶ ALL NALM-6, MOLM-13 cells
- ▶ U937 lymphoma cells
- ► A549 lung cancer cells
- ▶ HCT-116 colon cancer cells

Immortalized myoblasts

#### **Primary cells**

- Mononuclear cells from peripheral blood
- Bone marrow stromal cells
- Skin fibroblasts
- Vascular smooth muscle cells
- Endothelial cells
- Cord blood derived mesenchymal stem cells
- ▶ Rat primary sympathetic neurons

#### **Animal models**

- Systemic injection of siRNA
- Local injection of siRNA
- Local injection and implantation of pDNA expression vectors
- ▶ Local injection of mRNA
- Combinational delivery of multiple nucleic acids

**Novel delivery** platform

Wide applicability for different nucleic acids

Tailored for specific types of cells, with superb efficacy with blood and immune cells

**Seamless Translation** to preclinical animal models

**RJH Biosciences** © 2021



**RJH Biosciences Inc.**Suite 4000, 10230 Jasper Avenue, Edmonton, Alberta, T5J 4P6 CANADA

www.rjhbiosciences.com rjhbiosciences@gmail.com

Disclaimer. This document is prepared by RJH Biosciences and is only intended to provide information for the corresponding recipient. The recipient shall perform their own review, evaluation and assessment of the information presented. RJH Biosciences does not ensure any representations, warranties or assurances of the contents of the document. This document is not intended to be used as a solicitation, an offer to sell, or an offer to buy security in any jurisdiction. Distribution in or from specific prisdictions of this document may be prohibited or restricted by applicable laws or regulations. Recipients of the document must comply with all said restrictions in said jurisdictions. RJH Biosciences does not claim any liabilities with the use, misuse, reliance, distribution or possession of this document. Such misuse will therein be at the recipient's own risk. RJH Biosciences does not act for the recipients of this document. The provided documents and its contents may not be disclosed or used for alternative purpose without prior written consent from RJH Biosciences Inc.

v1.1